|
IRF4-Targeted Therapies for Cancer, Transplant Rejection, and Autoimmune Disorders
This invention is a method of depleting or over-expressing the transcription factor, interferon regulatory factor 4 (IRF4), in T cells as therapeutic strategy for conditions which are highly regulated by the immune system. The inventors have established that IRF4 represses PD-1, Helios, and other molecules associated with T cell function, representing...
Published: 10/8/2024
|
Inventor(s): Wenhao Chen, Xian Li
Keywords(s):
Category(s): Technology Classifications > Therapeutic > Cell and Gene Therapies, Clinical Area > Transplantation, Clinical Area > Cancer, Clinical Area > Metabolic Disease, Inflammation, and Immunology, Research Area > Cancer, Research Area > Immunobiology and Inflammation
|
